For colorectal adenomas, biennial screening increases diagnosis rates
the ONA take:
According to findings presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, screening patients biennially for colorectal cancer in a region of France increased the rate of diagnosis of high-risk polyps by 89%. Polyps, or adenomas, are pre-cancerous and a risk factor for developing colorectal cancer.
For the study, researchers identified patients aged between 50 and 74 years who were diagnosed with their first adenoma between 1997 and 2008. Of those, 38.7% had high-risk polyps. They found that the rate of diagnosis of pre-cancerous adenomas increased by 89% after the initiation of fecal occult blood testing. The rate of diagnosis of non-advanced adenomas increased by 68%.
The authors suggest that these results demonstrate that patients should be routinely screened for colorectal cancer as increased participation will improve success of screening programs.
Screening patients biennially for colorectal cancer increased rate of diagnosis by 89%.
The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk pre-cancerous adenomas (sometimes called polyps) by 89%, researchers have reported at the ESMO 2014 Congress in Madrid. Dr Vanessa Cottet from INSERM Unité 866 in Dijon, France, and colleagues studied the region of Côte-d'Or, where a registry has been collecting data on adenomas since 1976.
They wanted to evaluate the rate of diagnosis of adenomas before and after the initiation of a screening program using fecal occult blood testing that began in 2003. The study included all residents aged between 50 and 74 years of age who had a first adenoma identified between January 1997 and December 2008.
The researchers showed that 38.7% of these people had high-risk adenomas - meaning they were larger than 1 centimetre in diameter, involved the finger-like projections called villi in the intestinal lining, or exhibited a high grade of dysplasia.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Neuropathic Cancer Pain Linked to Reduced Quality of Life
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Opioids Overprescribed in Patients Undergoing Surgery
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|